Cooley advised LB Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases including schizophrenia, on its $285 million upsized initial public offering (IPO). Lawyers Brandon Fenn, Divakar Gupta, Marc Recht, Minkyu Park, Denny Xu, Danbi Kim, Ariane Andrade, Nathaniel Hearn and Karun Ahuja led the Cooley team advising LB Pharmaceuticals, with support from quantitative analyst Brandon Lefebvre.